{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:57:57Z","timestamp":1791903477033,"version":"4.3.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,5,19]],"date-time":"2011-05-19T00:00:00Z","timestamp":1305763200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1007\/s00280-011-1671-3","type":"journal-article","created":{"date-parts":[[2011,5,18]],"date-time":"2011-05-18T15:43:19Z","timestamp":1305733399000},"page":"539-545","source":"Crossref","is-referenced-by-count":36,"title":["PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma"],"prefix":"10.1007","volume":"68","author":[{"given":"Ghassan K.","family":"Abou-Alfa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Gabriela","family":"Chiorean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall F.","family":"Holcombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary F.","family":"Mulcahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashyap","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa J.","family":"Melink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Gutheil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Jung","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,19]]},"reference":[{"issue":"13","key":"1671_CR1","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1158\/1078-0432.CCR-07-0478","volume":"13","author":"AV Patterson","year":"2007","unstructured":"Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, Pullen SM, Hicks KO, Syddall SP, Atwell GJ, Yang S, Denny WA, Wilson WR (2007) Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res 13(13):3922\u20133932","journal-title":"Clin Cancer Res"},{"key":"1671_CR2","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1158\/1535-7163.MCT-08-1209","volume":"8","author":"Y Gu","year":"2009","unstructured":"Gu Y, Patterson AV, Atwell GJ, Chernikova SB, Brown JM, Thompson LH, Wilson WR (2009) Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Mol Cancer Ther 8:1714\u20131723","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"1671_CR3","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1158\/0008-5472.CAN-08-4023","volume":"69","author":"RS Singleton","year":"2009","unstructured":"Singleton RS, Guise CP, Ferry DM, Pullen SM, Dorie MJ, Brown JM, Patterson AV, Wilson WR (2009) DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity. Cancer Res 69(9):3884\u20133891","journal-title":"Cancer Res"},{"key":"1671_CR4","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ijrobp.2007.05.049","volume":"69","author":"KO Hicks","year":"2007","unstructured":"Hicks KO, Myint H, Patterson AV, Pruijn FB, Siim BG, Patel K, Wilson WR (2007) Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. Int J Radiat Oncol Biol Phys 69:560\u2013571","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1671_CR5","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.bcp.2007.06.014","volume":"74","author":"CP Guise","year":"2007","unstructured":"Guise CP, Wang A, Theil A, Bridewell DJ, Wilson WR, Patterson AV (2007) Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR104A: a role for NADPH-cytochrome P450 oxidoreductase under hypoxia. Biochem Pharmacol 74:810\u2013820","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"1671_CR6","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1158\/0008-5472.CAN-09-3237","volume":"70","author":"CP Guise","year":"2010","unstructured":"Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, Do\u00f1ate F, Wilson WR, Patterson AV (2010) The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res 70(4):1573\u20131584","journal-title":"Cancer Res"},{"issue":"4","key":"1671_CR7","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00280-009-1188-1","volume":"65","author":"MB Jameson","year":"2010","unstructured":"Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson AV, Denny WA, Wilson WR (2010) A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol 65(4):791\u2013801","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"1671_CR8","first-page":"1178","volume":"22","author":"X-Z Wu","year":"2008","unstructured":"Wu X-Z, Xie G-R, Chen D (2008) Hypoxia and hepatocellular carcinoma: the therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol 22(8):1178\u20131182","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"1671_CR9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.tox.2007.10.029","volume":"246","author":"IM Copple","year":"2008","unstructured":"Copple IM, Goldring CE, Kitteringham NR, Park BK (2008) The Nrf2-Keap1 defense pathway: role in protection against drug-induced toxicity. Toxicology 246(1):24\u201333","journal-title":"Toxicology"},{"key":"1671_CR10","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wikie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099\u20137109","journal-title":"Cancer Res"},{"key":"1671_CR11","doi-asserted-by":"crossref","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, H\u00e4ussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J for the SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378\u2013390","DOI":"10.1056\/NEJMoa0708857"},{"key":"1671_CR12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"A-L Cheng","year":"2009","unstructured":"Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang T-S, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 10:25\u201334","journal-title":"Lancet Oncol"},{"key":"1671_CR13","unstructured":"Abbattista M, Guise CP, Jamieson S, Wu C, Li J, Sun K, Pullen SM, Gu Y, Patterson AV and Wilson WR (unpublished data)"},{"issue":"5","key":"1671_CR14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00280-006-0393-4","volume":"59","author":"YS Chang","year":"2007","unstructured":"Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A, Wilkie D, Carter CA, Taylor IC, Lynch M, Wilhelm S (2007) Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59(5):561\u2013574 (Epub 2006 Dec 8)","journal-title":"Cancer Chemother Pharmacol"},{"key":"1671_CR15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"1671_CR16","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1016\/j.jchromb.2009.08.009","volume":"877","author":"Y Gu","year":"2009","unstructured":"Gu Y, Wilson WR (2009) Rapid and sensitive ultra-high-pressure liquid chromatography-tandem mass spectrometry analysis of the novel anticancer agent PR-104 and its major metabolites in human plasma: application to a pharmacokinetic study. J Chrom B 877:3181\u20133186","journal-title":"J Chrom B"},{"key":"1671_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/dmd.109.028142","volume":"38","author":"Y Gu","year":"2010","unstructured":"Gu Y, Atwell GJ, Wilson WR (2010) Metabolism and excretion of the novel bioreductive prodrug PR-104 in mice, rats, dogs and humans. Drug Metab Dispos 38:1\u201311","journal-title":"Drug Metab Dispos"},{"key":"1671_CR18","doi-asserted-by":"crossref","unstructured":"Patel K, Choy SSF, Hicks, KO, Melink, TJ, Holford NHG, Wilson WR (2010) A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity. Cancer Chemother Pharmacol, published on-line 3 Aug 2010. doi: 10.1007\/s00280-010-1412-z","DOI":"10.1007\/s00280-010-1412-z"},{"key":"1671_CR19","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1073\/pnas.0701152104","volume":"104","author":"K Parmar","year":"2007","unstructured":"Parmar K, Mauch P, Vergilio J, Sackstein R, Down JD (2007) Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 104:5431\u20135436","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1671-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-011-1671-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1671-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T22:13:15Z","timestamp":1560204795000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-011-1671-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,19]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["1671"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1671-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,19]]}}}